IDH2 and central nervous system cancer: Around 80% of grade II and III astrocytomas, oligodendrogliomas, secondary GBM, and tumors that develop from lower-grade gliomas exhibit alterations in the genes responsible for IDH1 or, less frequently, IDH2 [3].